Modulators of sphingosine phosphate receptors

Patent metadata

Field	Value
Publication number	US-9382217-B2
Application number	US-201414311825-A
Country	US
Kind code	B2
Filing date	Jun 23, 2014
Priority date	May 14, 2008
Publication date	Jul 5, 2016
Grant date	Jul 5, 2016

Abstract

Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.

First claim

What is claimed is:

1. A method of treatment of a malcondition in a patient having such malcondition, wherein the malcondition is multiple sclerosis, transplant rejection or adult respiratory distress syndrome, comprising administering to the patient an effective dose of a compound of formula (I), or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof:

wherein
a dashed line signifies that a single bond or a double bond can be present, provided that there are two double bonds and three single bonds in the ring comprising A 1 , A 2 , and A 3 ;
A 1 and A 3 are N and A 2 is O;
L 1 and L 2 are each independently a bond;
J independently at each occurrence is F, Cl, Br, I, OR′, OC(O)N(R′) 2 , CN, CF 3 , OCF 3 , R′, methylenedioxy, ethylenedioxy, N(R′) 2 , SR′, SOR′, SO 2 R′, SO 2 N(R′) 2 , SO 3 R′, C(O)R′, C(O)C(O)R′, C(O)CH 2 C(O)R′, C(S)R′, C(O)OR′, OC(O)R′, OC(O)OR′, C(O)N(R′) 2 , OC(O)N(R′) 2 , C(S)N(R′) 2 , (CH 2 ) 0-2 NHC(O)R′, N(R′)N(R′)C(O)R′, N(R′)N(R′)C(O)OR′, N(R′)N(R′)CON(R′) 2 , N(R′)SO 2 R′, N(R′)SO 2 N(R′) 2 , N(R′)C(O)OR′, N(R′)C(O)R′, N(R′)C(S)R′, N(R′)C(O)N(R′) 2 , N(R′)C(S)N(R′) 2 , N(COR′)COR′, N(OR′)R′, C(═NH)N(R′) 2 , C(O)N(OR′)R′, or C(═NOR′)R′, wherein R′ is independently at each occurrence hydrogen or an alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl wherein any alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is substituted with 0-3 J;
R 5 a group of formula a-i

mono- or pluri-substituted with J, wherein a wavy line indicates a point of attachment;
R 6 is phenyl mono- or pluri-substituted with J.

2. The method of claim 1 wherein the malcondition is transplant rejection or adult respiratory distress syndrome.

3. The method of claim 1 wherein the malcondition is multiple sclerosis.

Assignees

• Scripps Research Inst

Inventors

• Roberts Edward
• Rosen Hugh
• Brown Steven
• Guerrero Miguel A
• Peng Xuemei
• Poddutoori Ramulu

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• C07D413/04 Primary

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title